Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 7/2017

01-07-2017 | Case Based Review

Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?

Authors: Ewa Więsik-Szewczyk, Aleksandra Kucharczyk, Katarzyna Świerkocka, Elżbieta Rutkowska, Karina Jahnz-Różyk

Published in: Clinical Rheumatology | Issue 7/2017

Login to get access

Abstract

A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.
Literature
1.
Hagberg KW, Li L, Peng M, Paris M, Shah K, Jick SS (2016) Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis. J Clin Rheumatol 22:241–247CrossRefPubMedPubMedCentral
2.
Haroon N, Inman RD (2009) Infectious complications of biological therapy. Curr Opin Rheumatol 21:397–403CrossRefPubMed
3.
Furst DE (2009) Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 39:18–29CrossRefPubMed
4.
Blot M, Boyer P, Samson M et al (2014) Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. Eur J Intern Med 25:837–842CrossRefPubMed
5.
Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 78:241–245CrossRefPubMed
6.
Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, Fieschi C, Thorn V, Abedi MR, Hammarstrom L (2008) Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277–286CrossRefPubMed
7.
Gathmann B, Mahlaoui N, CEREDIH et al (2014) Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 134:116–126CrossRefPubMed
8.
ESID Working Definitions for diagnosis of PID. file:///C:/Users/Samsung/Downloads/ESIDRegistry_ClinicalCriteria%20(5).pdf
9.
Bonilla FA, Barlan I, Chapel H et al (2016) International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract 4:38–59CrossRefPubMed
10.
Wirsum C, Glaser C, Gutenberger S et al (2016) Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol 36:406–412CrossRefPubMed
11.
Makatsori M, Kiani-Alikhan S, Manson AL et al (2014) Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes. QJM 107:821–828CrossRefPubMed
12.
Boileau J, Mouillot G, Gerard L et al (2011) Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun 36:25–32CrossRefPubMed
13.
Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J (2005) Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine 72:503–514CrossRefPubMed
14.
Swierkot J, Lewandowicz-Uszynska A, Chlebicki A, Szmyrka-Kaczmarek M, Polańska B, Jankowski A, Szechiński J (2006) Rheumatoid arthritis in a patient with common variable immunodeficiency: difficulty in diagnosis and therapy. Clin Rheumatol 25:92–94CrossRefPubMed
15.
Lin LH, Tsai CN, Liu MF, Wang CR (2005) Common variable immunodeficiency mimicking rheumatoid arthritis with Sjögren’s syndrome. J Microbiol Immunol Infect 38:358–360PubMed
16.
Diamantopoulos AP, Haugeberg G (2012) Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs. Mod Rheumatol 22:295–297CrossRefPubMed
17.
Xiao X, Miao Q, Chang C, Gershwin ME, Ma X (2014) Common variable immunodeficiency and autoimmunity—an inconvenient truth. Autoimmun Rev 13:858–864CrossRefPubMed
18.
Dimitriades VR, Sorensen R (2016) Rheumatologic manifestations of primary immunodeficiency diseases. Clin Rheumatol 35:843–850CrossRefPubMed
19.
Stiehm ER, Keller MA, Vyas GN (2008) Preparation and use of therapeutic anti-bodies primarily of human origin. Biologicals 36:363–374CrossRefPubMed
20.
Bonilla FA (2016) Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 37:426–431CrossRefPubMed
21.
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H (2010) Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354–1360.e4CrossRefPubMed
22.
Quinti I, Agostini C, Tabolli S, Brunetti G, Cinetto F, Pecoraro A, Spadaro G (2012) Malignancies are the major cause of death in patients with adult onset common variable immunodeficiency. Blood 120:1953–1954CrossRefPubMed
23.
Ammann EM, Jones MP, Link BK et al (2016) Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood 127:200–207CrossRefPubMedPubMedCentral
Metadata
Title
Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?
Authors
Ewa Więsik-Szewczyk
Aleksandra Kucharczyk
Katarzyna Świerkocka
Elżbieta Rutkowska
Karina Jahnz-Różyk
Publication date
01-07-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 7/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3670-1

Other articles of this Issue 7/2017

Clinical Rheumatology 7/2017 Go to the issue

Review Article

IL-6 blockade in the management of non-infectious uveitis

Brief Report

Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort

Brief Report

NLRP12 autoinflammatory disease: a Chinese case series and literature review

Letter to the Editor

Presidents’ Day reflections. Why Donald Trump could not be a rheumatologist

Letter to the Editor

Response to “Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial”

Original Article

Improving skills in pediatric rheumatology in Colombia: a combined educational strategy supported by ILAR

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits